DarioHealth Q4 revenue beats estimates, net loss narrows on lower expenses

Overview

• Digital health platform's Q4 revenue rose sequentially and beat analyst expectations

• Q4 net loss and operating loss both narrowed and beat analyst expectations

• Company says full-year revenue decline due to loss of single legacy client, not demand

Outlook

• Company expects contracted ARR of $12.9 mln to contribute revenue in 2026 and 2027

• DarioHealth expects non-GAAP operating loss to decrease by 30% in 2026

• Company anticipates continued expansion of MSK product in international markets

Result Drivers

• NEW ARR CONTRACTS - Sequential Q4 revenue growth driven by acceleration in new annual recurring revenue contracts from large employers and health plans

• OPERATING EFFICIENCIES - Lower operating expenses in Q4 attributed to post-merger integration activities and increased operational efficiency

• MSK PRODUCT DEMAND - Increased demand for musculoskeletal product in B2C market, with 36% growth in Q4

Company press release: ID:nPn9JHH1Xa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for DarioHealth Corp is $20.00, about 124% above its March 18 closing price of $8.93

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.